Mr. Birch’s presentation will focus on the market opportunities driven by increasing industry demand for a best-in-class, truly-unified clinical trial solutions. The Company’s DATATRAK ONE™ solution provides customers a unified approach to product and services delivery that ensures the safety, simplicity, and speed of clinical trials.

To view the live webcast of Mr. Birch’s presentation click here at 3:40 PM ET on Monday, September 13th. An archived recording of the presentation will also be available on DATATRAK’s website at www.datatrak.net.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT:
Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025

“DATATRAK prides itself on its stringent Quality Management System, and while this certification is new, our application was based on existing policy and procedures,” stated Shiela McLaughlin, International Director Quality Assurance. “Obtaining this certification is just one more way that DATATRAK is providing superior customer service to its clients.”

About Safe Harbor

The safe harbor — approved by the EU in 2000 — is an important way for U.S. companies to avoid experiencing interruptions in their business dealings with the EU or facing prosecution by European authorities under European privacy laws. Certifying to the safe harbor will assure that EU organizations know that your company provides “adequate” privacy protection, as defined by the Directive. For more information on the Safe Harbor certification, please see http://www.export.gov/safeharbor/.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT:
Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025

Cleveland, Ohio, USA – DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the second quarter of 2010: $1.9 million revenue, $10.9 million backlog, and continued profitability, resulting in a cash increase over first quarter 2010.

“DATATRAK’s growth continues, fueled by enhanced backlog, profitability and a balance sheet free of debt,” stated Laurence P. Birch, DATATRAK’s Chairman of the Board. “The word is getting out that DATATRAK is back in the game, as evidenced by the significant increase in traffic through our booth at the recent DIA meeting, which resulted in over 500 qualified leads. We started the year with an entire organization focused on customer service, long-term scalability and continued product expansion, and I’m happy to report that this focus coupled with the Safety, Simplicity and Speed of our unified solution continues to drive the company forward. We expect to build upon these recent successes through planned growth of the DATATRAK ONE™ solution by increasing marketing initiatives, further expanding into international markets and a fall release of the latest version of our eClinical software.”

Business Highlights

• Second consecutive quarterly profit
• The June 30, 2010 cash balance of $924,000 was an increase over the March 31, 2010 cash balance of $811,000 – the Company’s first positive cash flow from operations since 2006, allowing us to continue to invest in the growth of the company
• Both the 2010 second quarter revenue of $1.9 million and the gross profit margin of 85% are increases over the previous quarter as well as the same quarter in 2009
• Continued increase in backlog
• Backlog increased from $9.5 million at December 31, 2009 to $10.9 million at June 30, 2010
• Represented the fourth consecutive quarter-over-quarter increase in backlog
• Expanded strategic partnership in Japan with NTT DATA
• DATATRAK and NTT DATA entered an agreement to allow NTT DATA to sell Enterprise Transfer services within the Japanese market
• NTT DATA entered into its first third-party multi-year Enterprise Transfer agreement producing additional revenue streams for both NTT DATA and DATATRAK
• Sales pipeline expansion
• 2010 second quarter new contracts of $1.832 million represented a 250% increase over new contracts of $524,000 in the same period of 2009
• Signed first Portuguese client – CRO Keypoint Scientific Consultancy
• Debt free Balance Sheet
• Continued marketing efforts
• Exhibited at the 2010 ASCO Annual Meeting, including the introduction of the DATATRAK oncology offering
• Exhibited at the DIA 26th Annual Meeting, including the premiere of the DATATRAK Safety Case Manager™
• Presented at the 2010 OneMedForum in New York
• Recognized as 2010 Crain’s Leading Edge Award Winner
• Continued product enhancements
• Provided seamless experience for DATATRAK eClinical™ on the Apple® iPad™ through cross-browser compatibility
• Expanded offering to include Safety Export
• Further enhanced the standards in DATATRAK’s growing library, which now includes the HL7 import of ECGs and CDISC SDTM data export, XML export to E2B in the Safety Export, use of CDISC and CDASH field naming and exports using the CDISC Study Data Tabulation Model (SDTM)

Financial Highlights

Revenue for the second quarter of 2010 increased to $1,881,000 compared to $1,831,000 in the same period of 2009. Gross profit margin improved to 85% for the three months ended June 30, 2010 compared to 75% for the three months ended June 30, 2009. The improvement in the Company’s gross margin reflects a 39% reduction in direct costs.

For the three months ended June 30, 2010, DATATRAK’s income from operations was $27,000 compared to a loss from operations of $(36,000) in the second quarter of the prior year. The prior year second quarter loss from operations of $(36,000) reflects the reversal of $154,000 of severance expense as a result of a negotiated settlement with a former executive officer of the Company. Selling, general and administrative expenses increased slightly by $108,000 in the second quarter of 2010 compared to the second quarter of 2009, mainly due to the Company’s focus on its marketing efforts. Net income for the second quarter of 2010 was $25,000, or $0.00 per share on both a basic and diluted basis compared to a net loss of $(39,000) in the second quarter of 2009, or $(0.00) per share on both a basic and diluted basis.

For the six months ended June 30, 2010, DATATRAK’s revenue decreased $359,000, or 9%, to $3,558,000, from $3,917,000 in the first half of 2009. Net income for the first half of 2010 was $34,000, or $0.00 per share on a basic and diluted basis, compared to a net loss of $(827,000), or $(0.06) per share on a basic and diluted basis, reported for the same period of 2009. Despite the decline in revenue, gross profit margin improved to 84% in the first six months of 2010 compared to 76% in the same period of last year. Compared to the prior year first half, combined direct cost and SG&A expenses decreased approximately $395,000, or 10%, in the first half of 2010.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in the United States and Europe. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially for those contemplated in these forward looking statements please see the Company’s press release filed March 31, 2010 announcing its fourth quarter and full year results for 2009. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK International, Inc., +1-440-443-0082

“We have decided to use DATATRAK because the unified platform appealed to our needs. The ease in which for example IWRS or study drug management can be utilized with EDC within one solution will bring us significant benefit throughout the study. Furthermore, the built-in data export routines to SDTM and flexible ad-hoc reporting tools supporting our efforts in process control.” said Paul-Egbert Reimitz, Director of Biostatistics and Data Operations at DAIICHI SANKYO EUROPE GmbH.

“We are delighted to have been awarded this new study by DAIICHI SANKYO EUROPE, whose adoption of DATATRAK ONE™ is a testament to both teams’ hard work and success in implementing complex international clinical trials,” said Laurence P. Birch, DATATRAK’s Chairman of the Board. “We remain focused on providing our clients the benefits of increased patient safety, real-time data availability and management in addition to a completely unified user experience, ranging from investigative sites to Sponsors and CROs.”

About DAIICHI SANKYO

DAIICHI SANKYO is a global pharmaceutical company that focuses on research and the marketing of innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly € 7.3 billion in fiscal year 2009 (as at March 31st), DAIICHI SANKYO is one of the world’s 20 leading pharmaceutical companies. The company’s world headquarters is in Tokyo. Its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries, and one of its global manufacturing sites is located in Pfaffenhofen, a town in the German state of Bavaria. The company’s research activities focus on the areas of cardiovascular diseases, hematology, anti-infectives and cancer. Its aim is to develop medications that are best in their class or create a new class of active ingredients.
For more information, please visit: www.daiichi-sankyo.eu

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas.
For more information, visit www.datatrak.net

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially for those contemplated in these forward looking statements please see the Company’s press release filed March 31, 2010 announcing its fourth quarter and full year results for 2009. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK International, Inc., +1-440-443-0082 x 143

In addition, DATATRAK announced that prior to the private placement, Laurence P. Birch, its Chairman of the Board, purchased 185,824 common shares of DATATRAK for his own account in open market transactions.

“The purchase of these common shares demonstrates the continuing commitment of our Board and management team to DATATRAK,” stated Mr. Birch. “The company’s recent successes have indeed energized and inspired the individuals charged with overseeing the future of DATATRAK.”

DATATRAK also announced that it had entered into an employment agreement with Mr. Birch, effective July 1, 2010. This agreement memorializes the arrangement under which Mr. Birch has been acting as DATATRAK’s Chief Executive Officer and President and contains additional provisions relating to payment, under certain circumstances, of potential severance and other compensation. A copy of Mr. Birch’s employment agreement shall be included as an Exhibit to DATATRAK’s quarterly report for the quarter ended June 30, 2010.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK International, Inc., +1-440-443-0082 x 143

Mr. Birch’s presentation will focus on the market opportunities driven by increasing industry demand for a bestin- class, truly-unified clinical trial solution. DATATRAK provides customers a unified system assuring safety, simplicity, and speed.

About OneMedForum

The OneMedForum has broadened its reach to the East Coast-New York with its inaugural finance forum following the success of its annual conference held in San Francisco, each January. The OneMedPlace finance forum’s connect emerging healthcare and life science companies with investors and strategic partners. Over 75 company presentations will occur by some of the most promising – and typically least recognized – companies in the world. For more information, please visit www.onemedplace.com/onemedforum/.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK International, Inc., +1-440-443-0082 x 143

“We were impressed with the knowledge and sophistication of those that visited us at the show. The industry is no longer satisfied with a stand-alone EDC offering but a fully functioning clinical solution — which we have. This allows us to provide solutions to specific and complex clinical challenges not addressed by their current system.” said Laurence P. Birch, DATATRAK’s Chairman of the Board. He continued, “Customers, prospects and even our competitors are validating a unified solution as the best approach because it enhances the safety, simplicity and speed of clinical trials allowing customers to obtain high quality data more efficiently while simultaneously lowering costs.”

During the past year, the five-year old unified DATATRAK eClinical™ platform further evolved to seamlessly incorporate more than 200 new customer requested features, and DATATRAK revitalized its professional services offerings as DATATRAK ONE™, a unified approach to clinical support centered on its eClinical platform. At DIA, a captive audience viewed demonstrations of a few of these new features such as: expanded libraries, enhanced import and export tools, state of the art workflow, and a new safety case management offering.

As DATATRAK closed out the 46th annual DIA show, it looks forward to increasing sales, enhancing backlog, profitability and a balance sheet free of debt while harnessing the momentum of DATATRAK ONE™ on clinical development. The market is beginning to see a quantifiable difference between a truly unified solution and the traditional integrated software approach on their overall clinical development costs, not just their technology costs. Even more important is the integrity of data which may be subject to scrutiny when derived from an integrated system. As a leading choice for clinical trials along with a strong Partner Network, DATATRAK ONE™ delivers the solution to the industry’s need for safety, simplicity and speed.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning theoperations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK International, Inc., +1-440-443-0082 x 143

“Patient safety is a high priority at DATATRAK. We are pleased to leverage the capabilities of our unique unified platform to minimize the risk to patients who participate in clinical studies,” said Laurence Birch, DATATRAK’s Chairman of the Board. “The Safety Case Manager creates data reconciliation efficiencies and complements existing safety functions in DATATRAK’s Unified Clinical Research Suite.”

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK International, Inc., +1-440-443-0082 x 143